Bristol-Myers Squibb Company (BMY): BCG Matrix [June-2026 Updated]

Get a ready-made, research-based BCG Matrix Analysis of Bristol-Myers Squibb Company Business that quickly maps Stars like Breyanzi, Camzyos, and Reblozyl; Cash Cows like Eliquis and Opdivo; Question Marks such as Iberdomide, Mezigdomide, Pumitamig, and Sotyktu; and Dogs including Revlimid and other legacy brands. It highlights key portfolio facts such as $6.2 billion growth-portfolio revenue in Q1 2026, $5.3 billion legacy revenue, $11.5 billion total Q1 revenue, 55% growth-portfolio share, 70.2% GAAP gross margin, and the company's $10 billion annual R&D and capital-allocation priorities. Ideal as a study reference, research starting point, or support for coursework, case studies, presentations, and business analysis projects.

Bristol-Myers Squibb Company - BCG Matrix Analysis: Stars

Bristol-Myers Squibb's Star assets are concentrated in its growth portfolio, which produced $6.2 billion in Q1 2026 revenue and grew 9% ex-FX, following 16% year-over-year growth in Q4 2025. This segment accounted for about 55% of total revenue in late 2025 and is expected to remain above 50% for full-year 2026. The portfolio is anchored by Breyanzi, Camzyos, and Reblozyl, with seven products surpassing $1 billion in annualized sales by mid-2026. Management's target of 10+ new medicines and 30+ new indications by 2030 reinforces the high-growth profile of these assets.

Breyanzi is one of the clearest Star assets in Bristol-Myers Squibb's portfolio. It helped drive the growth portfolio's rise to $6.2 billion in Q1 2026 and contributed to the broader 16% year-over-year growth reported in Q4 2025 for the same segment. Its performance is supported by approximately $10 billion in annual R&D spending and more than 10 expected pivotal readouts in late 2026, which creates a continuous runway for label expansion, clinical validation, and commercial scale-up.

The scale of the company's overall platform strengthens Breyanzi's Star status. Bristol-Myers Squibb reported $11.5 billion in total revenue in Q1 2026, showing that Breyanzi is expanding inside a very large commercial base rather than a niche launch environment. With growth portfolio revenue already representing about 55% of late-2025 sales, Breyanzi sits in the most strategically important part of the company's business mix.

• Q1 2026 growth portfolio revenue: $6.2 billion
• Q4 2025 year-over-year growth: 16%
• Annual R&D spending: about $10 billion
• Expected pivotal readouts in late 2026: more than 10
• Total company revenue in Q1 2026: $11.5 billion

Camzyos also fits squarely into the Star quadrant because it is still expanding within a high-growth setting. The FDA's acceptance of the supplemental application for adolescent use on 2026-04-30, with a PDUFA date of 2026-09-30, opens a meaningful label-extension pathway beyond its established adult oHCM franchise. That matters because Camzyos is not merely defending a mature position; it is moving into a broader demand category while the company's growth portfolio continues to expand at scale.

Camzyos benefits from portfolio momentum rather than standing alone. The growth portfolio's 9% ex-FX Q1 increase and 16% Q4 increase indicate that the surrounding commercial environment remains supportive. Bristol-Myers Squibb's 2030 goals of 10+ new medicines and 30+ new indications also show that label expansion is a central strategic priority, not an isolated event. In this setting, Camzyos is better viewed as a Star asset with room for continued penetration and lifecycle growth.

Reblozyl is another Star because it was explicitly cited as a lead driver of the growth portfolio's Q1 2026 revenue increase to $6.2 billion. It operates within a portfolio that made up about 55% of late-2025 revenue and is projected to remain above 50% in 2026, which gives it a strong commercial base and visible operating leverage. By mid-2026, seven growth assets had annualized sales above $1 billion, placing Reblozyl among assets with meaningful scale and sustained strategic relevance.

Bristol-Myers Squibb's continued investment posture also supports the Star profile of Reblozyl and the broader growth portfolio. The company has maintained annual R&D near $10 billion and continued business development activity, including the $15.2 billion Hengrui oncology agreement, to strengthen pipeline depth and commercial optionality. This combination of internal innovation and external dealmaking helps sustain assets that are already generating significant revenue while still benefiting from high-growth market dynamics.

Reblozyl's placement in the Star quadrant is reinforced by the relationship between scale and growth. With quarterly total revenue at $11.5 billion and the growth portfolio delivering $6.2 billion in Q1 2026, Reblozyl is part of the company's revenue core rather than a peripheral contributor. The asset's leadership role within a portfolio that is still expanding at a high rate makes it a classic Star: high share, high growth, and strategically essential.

• Seven growth products exceeded $1 billion in annualized sales by mid-2026
• Growth portfolio expected to stay above 50% of full-year 2026 sales
• Company R&D commitment remains near $10 billion annually
• Hengrui oncology agreement value: $15.2 billion

Across Breyanzi, Camzyos, and Reblozyl, Bristol-Myers Squibb's Stars are concentrated in assets that combine strong growth rates, expanding indications, and large-scale commercial execution. The revenue mix, the magnitude of R&D support, and the pipeline cadence all point to a portfolio that is still in an acceleration phase, with these products carrying the highest strategic weight within the company's BCG matrix profile.

Bristol-Myers Squibb Company - BCG Matrix Analysis: Cash Cows

Eliquis remains the clearest cash cow in Bristol-Myers Squibb's portfolio because it continues to produce scale-level revenue with limited incremental growth, which is exactly the profile of a mature monetizer. In Q1 2026, the legacy portfolio still generated $5.3 billion in revenue even as other mature brands faced about 6% decline from generic pressure. Eliquis demand offset that weakness, preserving the cash base and reinforcing the franchise's role as the company's primary funding engine. Bristol-Myers Squibb reported $11.5 billion in Q1 2026 revenue, $1.31 GAAP EPS, and $1.58 non-GAAP EPS, while maintaining its $0.63 quarterly dividend. The company also reduced debt by $10 billion ahead of schedule and reaffirmed 2026 revenue guidance at the upper end of $46.0 billion to $47.5 billion. Even with a projected $1.5 billion to $2.0 billion Eliquis step-down in 2027, the brand still fits the cash-cow category because it currently generates substantial cash with strong profitability.

Opdivo is the other mature oncology cash generator, supported by broad clinical and regulatory relevance and a large installed revenue base. On 2026-03-20, US and EU regulators expanded its approvals in classical Hodgkin lymphoma, extending the utility of a franchise that already sits in the legacy portfolio contributing $5.3 billion in Q1 2026 revenue and supporting the company's $48.2 billion FY2025 revenue base. Bristol-Myers Squibb posted 70.2% GAAP gross margin in Q1 2026, showing that these established specialty products continue to convert sales into strong gross profit. The company is funding about $10 billion in annual R&D and a $2 billion productivity program from this mature base, which indicates the franchise is still producing excess cash well beyond operating needs. That combination of scale, margin, and ongoing approvals places Opdivo firmly in the cash-cow bucket.

The broader legacy portfolio remains Bristol-Myers Squibb's funding base because it still produced $5.3 billion in Q1 2026 sales, a level large enough to finance strategic priorities despite a 6% decline. That cash generation supports about $10 billion in annual R&D spending and the $1.5 billion Orbital Therapeutics acquisition, demonstrating that mature assets are still underwriting future pipeline development. The same base also supports the 94th consecutive year of dividend payments and the $0.63 quarterly dividend declared on 2026-03-02. With Q1 total revenue at $11.5 billion and non-GAAP EPS at $1.58, the company continues to monetize mature assets efficiently. In BCG terms, this is the textbook cash-cow engine: modest growth, high cash conversion, and persistent capital funding capacity.

• Eliquis offsets generic erosion in other mature brands and anchors legacy cash flow.
• Opdivo gained additional support through expanded 2026 approvals in classical Hodgkin lymphoma.
• The legacy portfolio generated $5.3 billion in Q1 2026 revenue despite a 6% decline.
• Annual R&D spending of about $10 billion is financed largely from mature product cash flow.
• The company maintained a $0.63 quarterly dividend and extended its dividend record to 94 consecutive years.

Mature brands continue to finance capital allocation because Bristol-Myers Squibb completed $10 billion of debt reduction ahead of schedule in early 2026. It had already delivered $1 billion in savings in 2025 toward a $2 billion productivity target due by 2027, which shows management is harvesting operational efficiencies from an already established base. The quarter also showed 70.2% GAAP gross margin and 70.3% non-GAAP gross margin, levels that are consistent with high-margin biologics and specialty medicines. Management reaffirmed 2026 revenue guidance at the upper end of $46.0 billion to $47.5 billion, signaling that the cash base remains stable even as product mix evolves. That stable monetization is the hallmark of a cash cow, even with gradual portfolio maturation and future Eliquis pressure already visible.

Eliquis and Opdivo function as the most important cash cows because they combine established market positions with continuing profitability and sufficient scale to absorb pressure from generic competition and lifecycle transitions. Their contribution is not defined by rapid growth but by durable cash flow, margin strength, and the ability to finance R&D, acquisitions, dividends, and debt reduction. Even with a projected 2027 Eliquis step-down of $1.5 billion to $2.0 billion, Bristol-Myers Squibb's current cash generation profile remains strong enough to support portfolio reinvestment and shareholder returns. The company's mature brands continue to behave like high-yield assets in a low-growth environment, which is the core logic of a BCG cash-cow position.

Bristol-Myers Squibb Company - BCG Matrix Analysis: Question Marks

Iberdomide sits squarely in the Question Marks quadrant. The FDA accepted its NDA on 2026-02-17 and assigned a PDUFA action date of 2026-08-17, which confirms regulatory momentum but not commercial traction. The asset has no disclosed revenue, no market share base, and no post-launch contribution as of mid-2026. Bristol-Myers Squibb is supporting the program within a roughly $10 billion annual R&D engine and a late-2026 pipeline schedule that includes more than 10 pivotal readouts. With the company targeting 10+ new medicines and 30+ new indications by 2030, iberdomide is a strategically prioritized bet with high upside and unresolved market position.

Mezigdomide also remains a Question Mark because clinical promise has not yet translated into a commercial footprint. On 2026-03-09, Bristol-Myers Squibb disclosed positive Phase 3 SUCCESSOR-2 results, including a 52% reduction in progression-or-death risk in relapsed or refractory multiple myeloma. That efficacy signal strengthens the asset's strategic value, but the program still had no approval and no revenue contribution as of June 2026. In a portfolio where annual R&D investment is around $10 billion and more than 10 pivotal readouts are expected in late 2026, mezigdomide is a capital-intensive development asset with zero current share.

• Phase 3 SUCCESSOR-2 showed a 52% reduction in progression or death risk.
• No approval had been granted as of June 2026.
• No commercial revenue was disclosed.
• The asset depends on Phase 3 success translating into future launch uptake.

Pumitamig is another high-potential Question Mark. The ROSETTA Lung-02 Phase 2/3 data were presented at ASCO 2026 on 2026-05-30, and the company described the non-small cell lung cancer results as encouraging. Even so, the asset had not received approval and had not generated sales by June 2026. This matters because Bristol-Myers Squibb is deploying about $10 billion annually into R&D while expecting more than 10 pivotal readouts in late 2026, signaling a broad push to convert oncology science into future share. The company's $15.2 billion Hengrui oncology agreement further underscores how aggressively capital is being placed behind oncology growth bets.

• ROSETTA Lung-02 results were presented at ASCO 2026 on 2026-05-30.
• Non-small cell lung cancer data were described as encouraging.
• No approval was reported as of June 2026.
• No market share or revenue was disclosed.

Sotyktu became a Question Mark in a new indication after FDA approval for active psoriatic arthritis on 2026-03-06. It is the first TYK2 inhibitor approved for that market, which gives it an important regulatory advantage. However, the data provided do not include psoriatic arthritis revenue, prescription share, or penetration benchmarks, leaving its commercial scale unproven. Bristol-Myers Squibb is still operating with roughly $10 billion in yearly R&D spend and a long-term ambition of 10+ new medicines and 30+ new indications by 2030, so the product has strategic relevance but no confirmed market dominance in this new use case.

Across these assets, the common BCG Matrix pattern is clear: regulatory or clinical validation is present, but market share remains unproven or nonexistent. That combination is the defining feature of Question Marks. Bristol-Myers Squibb is backing these programs with a large development budget, a heavy late-stage readout calendar, and an explicit pipeline-expansion strategy. The result is a portfolio segment with significant optionality, but one that has not yet earned the stability or cash-generation profile of a Star or Cash Cow.

Bristol-Myers Squibb Company - BCG Matrix Analysis: Dogs

Revlimid is the clearest Dog in Bristol-Myers Squibb's portfolio because its erosion accelerated sharply in Q1 2026. Sales fell 63% year over year to $349 million, driven by generic competition and a rapidly shrinking market position. That decline landed inside a legacy portfolio that was already down 6% to $5.3 billion for the quarter, while total company revenue still reached $11.5 billion. The contrast is important: Revlimid's remaining contribution is now much smaller relative to the $6.2 billion growth portfolio, and the product no longer supports the kind of volume or pricing power associated with a strong BCG position. Gross margin also softened to 70.2% GAAP from 72.9% a year earlier, reflecting the weaker mix. A steep sales collapse, shrinking share, and sustained generic pressure make Revlimid a textbook Dog.

Generic impacted mature brands are also being pushed into Dog territory. Bristol-Myers Squibb reported that the legacy portfolio's Q1 2026 revenue fell to $5.3 billion, down 6%, as Eliquis demand was offset by generic pressure elsewhere. That legacy pool is now smaller than the growth portfolio, which contributed 55% of late-2025 revenue and more than half of expected 2026 revenue. Management also warned of a $1.5 billion to $2.0 billion Eliquis step-down in 2027 from the IRA and 2028 patent expirations, reinforcing the erosion profile. In parallel, the company filed WARN notices for 206 additional layoffs in New Jersey, bringing planned 2025-2026 job cuts to about 1,000 positions, which is consistent with pruning weak lines. These mature, generic-exposed assets lack the growth and reinvestment profile of the Star bucket, so they sit in Dogs.

• Legacy portfolio Q1 2026 revenue: $5.3 billion.
• Legacy portfolio decline: 6% year over year.
• Growth portfolio share of late-2025 revenue: 55%.
• Expected 2026 revenue from growth portfolio: more than 50%.
• Expected Eliquis step-down: $1.5 billion to $2.0 billion in 2027.
• Planned 2025-2026 job cuts: about 1,000 positions.
• Additional New Jersey WARN notices: 206 employees.

The weakest legacy businesses are also acting as margin drag. Bristol-Myers Squibb's Q1 2026 gross margin fell to 70.2% GAAP and 70.3% non-GAAP from 72.9% a year earlier. Management tied the decline to product mix changes, meaning lower-quality revenue is displacing stronger specialty sales. The company still spends about $10 billion annually on R&D, so low-return mature assets are competing for capital against late-stage pipeline programs. Even after $10 billion of debt reduction and $1 billion of 2025 savings, cash must be redirected away from underperforming lines. In BCG terms, assets that dilute margin and require pruning are Dogs.

The legacy tail is contracting because the growth portfolio already held about 55% of late-2025 revenue, leaving a shrinking share for older products. Q1 2026 total revenue was $11.5 billion, up only 3%, while the legacy portfolio fell 6% to $5.3 billion. Management reaffirmed revenue guidance only at the upper end of $46.0 billion to $47.5 billion and kept its strategic focus on incremental growth and business development. That means capital is being directed toward higher-growth launches, not the low-growth tail. The shrinking relative importance and weak growth profile make the remaining tail a Dog rather than a Cash Cow.

• Total Q1 2026 revenue: $11.5 billion.
• Total revenue growth: 3% year over year.
• Legacy portfolio revenue: $5.3 billion.
• Legacy portfolio growth: -6% year over year.
• Revenue guidance range: $46.0 billion to $47.5 billion.
• Management focus: incremental growth and business development.